Abstract

BackgroundGrade prognostic assessment (GPA) is widely used to evaluate the prognosis of non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). This study aimed to investigate whether lymph node status (LNS) could be included as one of the GPA variables for NSCLC with BMs.MethodsOverall, 586 patients with NSCLC and BMs were retrospectively analyzed. Overall survival stratified by LNS was analyzed using the Kaplan-Meier method. Multivariate analysis was also performed to identify independent prognostic factors using the Cox proportional hazards progression model. In the updated GPA index, prognostic factors and criteria of GPA score were weighted by effect magnitude relative risk (RR) and statistical significance.ResultsIn NSCLC patients with BMs, those with lymph node involvement had worse overall survival (mOS, 13.4 months vs. 25.9 months, P <0.001) than those without lymph node involvement. Multivariate analysis showed that LNS might be an independent prognostic factor (RR: 1.702, CI: 1.340–2.162, P <0.001). Finally, five prognostic factors including LNS, the age of the patient, Karnofsky performance status (KPS), the number of BMs, and extracranial metastases were enrolled in our novel GPA index. With the updated GPA index involving the N stage, survival analysis was also performed. Prognostic results were significantly different among these four subgroups (Class A vs. Class B, P=0.047; Class B vs. Class C, P<0.001; Class C vs. Class D, P=0.007).ConclusionsThese results indicate that LNS might be an indispensable prognostic factor in NSCLC with BM. The novel GPA model involving the N stage could provide more reliable evidence to estimate the survival of NSCLC patients with BMs.

Highlights

  • About 25%–40% of non-small cell lung cancer (NSCLC) patients experienced brain metastases (BMs) during their disease course [1, 2]

  • The median age was 55 years, prevalent histology was adenocarcinoma (87.5%), and epidermal growth factor receptor (EGFR) mutation status was detected in 109 patients (18.6%), including 57 patients of wild-type and 52 patients of mutant type

  • We demonstrated that traditional grade prognostic assessment (GPA) could be used to evaluate the prognosis of BM patients, especially when selecting the patients with the best or worse prognoses (Class A vs. Class B, P

Read more

Summary

Introduction

About 25%–40% of non-small cell lung cancer (NSCLC) patients experienced brain metastases (BMs) during their disease course [1, 2]. Grade prognostic assessment (GPA) has been widely used to evaluate the prognosis of NSCLC patients with BM and has provided evidence for clinicians to make treatment decisions. The original GPA index was composed of four prognostic factors: age of patients, Karnofsky performance status (KPS), number of BM, and extracranial metastases. NSCLC with BM is a systemic disease, and many factors affect its prognosis [11]; it is necessary to update the original GPA index. Grade prognostic assessment (GPA) is widely used to evaluate the prognosis of non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). This study aimed to investigate whether lymph node status (LNS) could be included as one of the GPA variables for NSCLC with BMs

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call